Stokes William, Venner Allison A, Buss Emily, Tipples Graham, Berenger Byron M
Alberta Precision Laboratories, Calgary, Alberta, Canada.
Department of Pathology and Laboratory Medicine, University of Alberta, Edmonton, Alberta, Canada.
J Med Microbiol. 2023 Feb;72(2). doi: 10.1099/jmm.0.001669.
Starting in December, 2020, the ID NOW was implemented throughout the province of Alberta, Canada (population 4.4 million) in various settings. ID NOW's test performance with SARS-CoV-2 Omicron variant BA.1 is unknown. To assess the ID NOW performance among symptomatic individuals during the BA.1 Omicron wave and compare it to previous SARS-CoV-2 variant waves. The ID NOW was assessed in two locations among symptomatic individuals: rural hospitals and community assessment centres (AC) during the period 5-18 January 2022. Starting 5 January, Omicron represented >95 % of variants detected in our population. For every individual tested, two swabs were collected: one for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RT-PCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW results. A total of 3041 paired samples were analysed (1139 RT-PCR positive). From this, 1873 samples were from 42 COVID-19 AC and 1168 from 69 rural hospitals. ID NOW sensitivity for symptomatic individuals presenting to community AC and rural hospitals was 96.0 % [95 % confidence interval (CI) 94.5-97.3 %, =830 RT-PCR positive], and 91.6 % (95 % CI 87.9-94.4 %, =309 RT-PCR positive), respectively. SARS-CoV-2 positivity rate was very high for both populations (44.3 % at AC, 26.5 % in hospital). Sensitivity of ID NOW SARS-CoV-2, compared to RT-PCR, is very high during the BA.1 Omicron wave, and is significantly higher when compared to previous SARS-CoV-2 variant waves.
从2020年12月开始，即时检测（ID NOW）在加拿大阿尔伯塔省（人口440万）的各种场所全面推行。ID NOW对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种BA.1的检测性能尚不清楚。为了评估在奥密克戎变种BA.1流行期间有症状个体中ID NOW的检测性能，并将其与之前的SARS-CoV-2变种流行情况进行比较。在2022年1月5日至18日期间，在两个地点对有症状个体的ID NOW进行了评估：农村医院和社区评估中心（AC）。从1月5日开始，奥密克戎变种在我们检测的人群中占比超过95%。对每个检测个体采集两份拭子：一份用于ID NOW检测，另一份用于对ID NOW阴性结果进行逆转录聚合酶链反应（RT-PCR）确认，或对ID NOW阳性结果进行变种检测。共分析了3041对样本（1139份RT-PCR阳性）。其中，1873份样本来自42个COVID-19社区评估中心，1168份来自69家农村医院。在社区评估中心和农村医院就诊的有症状个体中，ID NOW的敏感性分别为96.0%[95%置信区间（CI）94.5-97.3%，RT-PCR阳性830份]和91.6%（95%CI 87.9-94.4%，RT-PCR阳性309份）。这两个人群的SARS-CoV-2阳性率都非常高（社区评估中心为44.3%，医院为26.5%）。与RT-PCR相比时，ID NOW检测SARS-CoV-2的敏感性在奥密克戎变种BA.1流行期间非常高，并且与之前的SARS-CoV-2变种流行情况相比显著更高。
